A Study of Glycemic Control in Left Ventricular Assist
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.
Eligibility criteria
Qualifiers
Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010
Diagnosis of type II diabetes mellitus
Any antihyperglycemic regimen
Greater than 3 months out from LVAD implantation
Disqualifiers
Type I diabetics
Unable to return at 3 month evaluation
Unwillingness to participate
Trial design
Treatments tested in this trial
- Freestyle Libre 3 Continuous Glucose Monitor (CGM)
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov